key: cord-0796418-fi7a0qvj
authors: Parker, Catherine; Shalev, Daniel; Hsu, Ian; Shenoy, Akhil; Cheung, Stephanie; Nash, Sara; Wiener, Ilona; Fedoronko, David; Allen, Nicole; Shapiro, Peter A.
title: Depression, Anxiety, and Acute Stress Disorder among Patients Hospitalized with COVID-19: A Prospective Cohort Study
date: 2020-10-10
journal: Psychosomatics
DOI: 10.1016/j.psym.2020.10.001
sha: 52fc2efcc92b9e6c35c8f618036c57e96d12b797
doc_id: 796418
cord_uid: fi7a0qvj

OBJECTIVE: The epidemiology of psychiatric symptoms among COVID-19 patients is poorly characterized. This paper seeks to identify the prevalence of anxiety, depression, and acute stress disorder among hospitalized patients with COVID-19. METHODS: Adult patients recently admitted to non-ICU medical ward settings with COVID-19 were eligible for enrollment. Enrolled patients were screened for depression, anxiety, and delirium. Subsequently, patients were followed by phone after two weeks and re-screened for depression, anxiety, and acute stress disorder symptoms. Subjects’ medical records were abstracted for clinical data. RESULTS: 58 subjects were enrolled of whom 44 completed the study. Initially, 36% of subjects had elevated anxiety symptoms and 29% elevated depression symptoms. At two-week follow-up, 9% had elevated anxiety symptoms, 20% elevated depression symptoms, and 25% mild-to-moderate acute stress disorder symptoms. Discharge to home was not associated with improvement in psychiatric symptoms. CONCLUSION: A significant number of patients hospitalized with COVID-19 experience symptoms of depression and anxiety. While anxiety improves following index admission, depression remains fairly stable. Furthermore, a significant minority of patients experience acute stress disorder symptoms, though these are largely mild-to-moderate.

Coronavirus disease 2019 (COVID-19) is a viral illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which emerged in China in late 2019 and was declared a pandemic by the World Health Organization on March 11, 2020. 1 Since its emergence, COVID-19 has infected over 21 million people and caused over 750,000 deaths. 2 As of late September 2020, it continues to spread unabated throughout the world. Viral epidemics and pandemics including H1N1 influenza, Ebola, and Zika, were associated with neuropsychiatric disorders due to both direct effects of infection and psychosocial-economic factors associated with epidemics. 3, 4 More specifically, severe epidemic coronaviruses such as Severe Acute Respiratory Syndrome (SARS-CoV-1) and Middle East Respiratory Syndrome (MERS) were associated with a high prevalence of psychiatric morbidity including mood, anxiety, and post-traumatic symptoms. 5, 6 Although COVID-19 differs from previous coronaviruses of the 21st century in incidence and distribution of disease, it has been hypothesized that its impact on mental health will be substantial. 7, 8 This impact is not limited to those directly infected by the virus; psychosocial stressors associated with the pandemic may exacerbate or precipitate psychiatric illness in uninfected individuals. Healthcare workers at the frontline are particularly vulnerable to a range of indirect psychiatric complications including PTSD, anxiety, and depression. 9, 10 The psychosocial impact on the general population and healthcare workers notwithstanding, there are reasons to believe that those directly infected with SARS-COV-2 are at particular risk of psychiatric complications during both the acute and recovery phases of illness. A number of putative mechanisms exist by which COVID-19 may induce psychiatric symptoms including 1) the virus's direct effect on the central nervous system, 2) the J o u r n a l P r e -p r o o f neuropsychiatric effects of systemic and central nervous system inflammation, 3) the psychological impact of contact-isolation and the stigma of infectious disease and 4) social role disruption and impairment in function associated with serious illness. 11 While early research examined the respiratory complications and constitutional symptoms of COVID-19, emerging evidence suggests that neuropsychiatric complications are prevalent in a large number of COVID-19 patients, particularly those with severe disease. 12,13 A collaborative case series from the United Kingdom documenting neurological and neuropsychiatric symptoms in 153 patients indicated that altered mental status was the most common neuropsychiatric symptom in the study population but did not focus on primary psychiatric symptoms like depression and anxiety. 14 Several surveys have sought to quantify mood symptoms in healthcare workers and patients with existing primary affective disorders; notably, these have been milieu studies investigating the impact of pandemic on individuals at large-not in those infected with SARS-2-CoV specifically. 15, 16 However, data from one cohort of patients with COVID-19 suggests high rates of anxiety, depression, and other psychiatric symptoms. 17 Patients admitted to the hospital for COVID-19 may be a population at especially increased risk of developing psychiatric symptoms given the severity of their disease, the unique stress of hospitalization under contact isolation, and the possibility of iatrogenic psychiatric effects of medications and other interventions.

In this prospective longitudinal cohort study our aim was to assess the point prevalence of neuropsychiatric symptoms in hospitalized COVID-19 patients using existing diagnostic screening tools administered remotely, and to identify associations between illness severity in COVID-19 admissions and psychiatric symptoms. While there is a growing body of literature regarding the effect of viral epidemic illnesses on mental health, these studies have been cross-J o u r n a l P r e -p r o o f sectional or retrospective in nature. To our knowledge, this study is the first to examine the prevalence of mood symptoms in patients hospitalized with COVID-19 in a prospective manner.

Eligible patients were enrolled during a one-month period at two sites at a large academic medical center-an urban tertiary care center and a community hospital-in New York City.

Following subject consent and enrollment, investigators administered a study entry survey and symptom assessment and contacted the participant's nurse to assess for delirium. Screening at study entry was performed 0 to 96 hours after an enrolled patient was admitted from the Intensive Care Unit (ICU) or Emergency Department to an inpatient (non-ICU) hospital service.

14 to 17 days after enrollment, investigators contacted participants for follow-up assessment.

Consent and assessments were administered by telephone. Additional data were retrieved from the medical record. (Figure 1) For participants whose responses indicated a clinically significant level of symptoms, the investigator informed the patient's primary team, so that the patient could be further assessed and offered psychiatric intervention when warranted. If the participant had been discharged to home or a rehabilitation facility, the investigator referred the participant to a complimentary mental health referral and resource hotline in New York City.

The Columbia University Irving Medical Center Institutional Review Board approved the study protocol; verbal informed consent was obtained from all participants prior to administration of survey and screening assessments. Investigators identified eligible patients using the hospital network's system-wide electronic medical record infection-control list, which enumerates all patients on isolation at a given time. If a patient appeared to meet criteria for enrollment, an investigator contacted the patient's primary care team using secure messaging to request they approach the patient for permission for the study team to contact them. If granted, a patient was called for informed consent and enrollment.

At time of study entry, investigators administered a survey to obtain a brief psychiatric history that queried existing diagnoses, treatment modalities, and history of prior psychiatric hospitalizations. The Hospital Anxiety and Depression Scale (HADS), a 14-item questionnaire used in adult patients with physical illness, was administered to determine symptoms of depression and anxiety. 18 Additionally, investigators asked the patient's primary nurse to complete the short form of the Confusion Assessment Method (sCAM), a 5-item validated tool used to screen for delirium in hospitalized adults. 19 J o u r n a l P r e -p r o o f At 2-week-follow up, participants were asked to repeat the HADS and to complete the National Stressful Events Survey Acute Stress Disorder Short Scale (NSESSS). 20 The NSESSS is a validated 7-item questionnaire used to measure the severity of symptoms consistent with acute stress disorder in adults; if symptoms of acute stress disorder persist for greater than one month, participants may develop post-traumatic stress disorder (PTSD). Because each item on the measure is rated on a 5-point scale, a raw composite score is divided by 7 to calculate an average total score; if the result is a fraction it is rounded to the nearest whole number. A score of 0 points suggests no acute stress disorder; 1 point corresponds to mild, 2 -moderate, 3severe, and 4 points to extreme symptoms.

Once study entry and follow-up assessments were completed, investigators performed a review of each participant's electronic medical record to abstract demographic data, clinical data, and details about the index hospital admission. Chart diagnoses were used to calculate a patient's Charlson Comorbidity score, which quantifies an individual's morbidity and mortality risk. 21 

The primary goal of the study was to describe the point prevalence of delirium, depressed mood, and anxiety among surveyed patients acutely hospitalized with coronavirus 2019 and the point prevalence of depressed mood, anxiety, and acute stress disorder at 2-weeks in this same population. A secondary aim was to determine if any risk factors predicted a higher prevalence of psychiatric symptoms in the study cohort. Specifically, we sought to test the hypotheses that 1) severity of illness as indexed by prior ICU stay and by inflammatory markers are associated with a more significant psychiatric symptom burden, and 2) discharge to home, rather than to rehabilitation or skilled nursing care is associated with lower symptoms at 2-week follow-up, on J o u r n a l P r e -p r o o f the premise that intensive care unit admission, inflammatory markers, and disposition correlate with disease severity and functional status.

We report characteristics of enrolled patients as counts and percentages. We report psychiatric screening scores stratified according to demographic and clinical characteristics.

Continuous variables are expressed as means and interquartile ranges. We did not impute missing data. As screening score results were not normally distributed and asymmetric, we used non-parametric tests to evaluate associations and mean differences. Spearman's rank correlation was used to calculate associations; the Mann-Whitney U Test, the non-parametric equivalent of the unpaired t-test, was used to compare means between two groups; and the Kruskall-Wallis test, the non-parametric equivalent of a one-way ANOVA, was used to compare means between multiple groups. Significance values were adjusted using the post-hoc Bonferroni correction for multiple tests. We analyzed all data using SPSS Statistics, version 27. At study entry, the HADS-A mean score was 5.4 points; 21 (36%) participants had anxiety symptom scores ≥ 8 points, a level denoting clinically significant symptoms. At twoweek follow-up, the HADS-A mean score was 3.4, with 4 (9%) participants scoring ≥ 8. The mean improvement in HADS-Anxiety scores from study entry to 2-weeks was 1.3 points. Upon study entry, the HADS-D mean score was 6.3 points, and 17 (29%) participants had depression symptom scores ≥ 8, suggesting clinical significance; at two-weeks, the HADS-D mean score was 4.2 with 9 participants (20%) scoring ≥ 8. The mean improvement in HADS-D was 1.2 points. At time of study entry, none of the enrollees screened positive for delirium by the sCAM.

The mean NSESSS score at 2-week follow-up was 0.78 points with 11 individuals (25%) scoring as experiencing mild or moderate symptoms of acute stress disorder. (Table 2 )

There were no demographic characteristics that predicted a statistically significant higher prevalence of psychiatric symptoms in the study cohort. Although more patients with a past psychiatric diagnosis screened positive for mood symptoms on admission than those without a psychiatric diagnosis, the difference was not statistically significant.

Regarding our hypothesis that severity of COVID-19 disease as indicated by admission to an intensive care unit during index hospitalization would be associated with a more significant psychiatric symptom burden, we found that patients admitted to an ICU prior to study entry (n=12) did not have a significantly higher prevalence of mood and acute stress disorder symptoms at either time point when compared to cohort peers not admitted to an ICU prior to study entry. However, ICU admission after study entry during index hospitalization was significantly associated with a higher prevalence of depression symptoms at time of study entry J o u r n a l P r e -p r o o f (n=5); the mean HADS-D score for this group at time of study entry was 10.8 points versus 5.9

for participants not admitted to the ICU during this same period (p= .027). Only 1 out of the 5 patients admitted to the ICU after study entry was clinically stable enough to participate in follow-up assessment, so we were unable to ascertain prevalence of mood symptoms in this group at 2-weeks. Length of stay was not associated with severity of psychiatric symptoms at either time point or mean improvement in mood symptoms.

Results did not confirm our hypothesis that final discharge to home would be associated with a higher mean improvement in mood symptoms at 2-week follow-up than among patients discharged to nursing homes or rehabilitation facilities.

With regard to inflammatory markers, the last interleukin-6 value measured prior to study entry was positively associated with a patient's HADS-A score at that time (r (21) =.443; p=.034); however, no associations between C-Reactive Protein or Erythrocyte Sedimentation Rate and psychiatric symptoms at either time point were identified.

We evaluated the severity of symptoms of anxiety and depression shortly after hospital admission or transfer out of intensive care in a prospective cohort of patients hospitalized with COVID-19 infection early in the course of the pandemic in New York City. We subsequently reassessed symptoms of anxiety, depression, and assessed symptoms of acute stress disorder approximately 2 weeks after the initial assessment. We found a substantial prevalence of clinically significant anxiety (36%) and depression (29%) symptoms on initial assessment. On follow-up, there was a significant reduction in anxiety symptoms, but a relative persistence of depressive symptoms. 25% of patients assessed at the follow-up point had mild-or-greater J o u r n a l P r e -p r o o f symptoms of acute stress disorder. Our results did not support our hypotheses that more severe illness, as indexed by prior ICU admission or elevated inflammatory markers, would be associated with more severe psychiatric symptoms, except for an association of IL-6 level with anxiety symptoms. Likewise, we did not find evidence that discharge to home rather than to another care facility was associated with greater improvement in psychiatric symptoms over the course of the study.

Our results extend those previously identified in the literature. In an Italian study of 402 COVID-19 patients evaluated in the emergency department and then screened for psychopathology approximately one month after initial emergency department evaluation, approximately 56% of patients screened positive in at least one psychiatric domain. Of these, approximately 31% screened positively for depression, 42% for anxiety, and 28% for obsessivecompulsive symptoms. 17 Based on the high prevalence of psychiatric symptoms reported in ICU survivors in existing literature, 23 we expected that participants who were admitted to the ICU during index hospitalization would have more mood and acute stress disorder symptoms than patients not requiring ICU admission; however, our study found no significant difference in symptom burden between cohorts. This finding may be due to the low power of the study or to eligibility criteria that excluded non-verbal and delirious patients, such that patients recruited from the ICU in our study were less severely ill than COVID-19 ICU admissions generally. In

index was correlated with depression and anxiety scores at follow-up. While our study did not detect a correlation between depressive symptoms and inflammation, this may have been due to our small sample size, and we did detect some degree of correlation between anxiety and inflammation. Our study represents a contribution to the understanding of psychiatric complications of COVID-19 infection. We identified a prospective cohort that were followed longitudinally between time of hospital admission over a two-week period (during which many were discharged). We utilized validated measures to screen for depression, anxiety, acute stress disorder, and delirium. Despite restrictions on in-person research involving individuals infected with COVID-19, we were able to maintain safety and progress in our data collection using telephone contact.

Our study has a number of limitations. Because only patients with capacity to provide informed consent were eligible to enroll, our data likely underestimate the prevalence of delirium. Of the 247 patients screened for eligibility, 80 could not be approached to consent to study participation due to cognitive impairment. We are unable to assess how many of these patients had new cognitive difficulty or delirium specifically associated with COVID-19 infection versus underlying dementia. Since study protocol required that screening be performed remotely, patients with respiratory symptoms requiring invasive support measures that rendered them non-verbal are under-represented making it difficult to ascertain fully the relationship between illness severity and psychiatric symptoms. Given non-English-speaking patients were excluded, our sample is not representative of the diverse population our hospital system serves; a large portion of our patient population is predominantly Spanish-speaking. Because of a rapid decline in the COVID-19 hospitalization rate that coincided with the period in which we enrolled patients, we were unable to achieve our target enrollment of 100 subjects; the small sample size increases the risk of Type 2 error in hypothesis testing. Lastly, our ability to follow participants beyond 2 weeks was constrained by available time and resources; a prospective cohort study that J o u r n a l P r e -p r o o f follows hospitalized COVID-19 patients months and years after discharge is needed to better characterize the psychiatric sequelae of this novel virus.

Among patients hospitalized with COVID-19 infection, there is a high prevalence of clinically significant symptoms of anxiety and depression. These symptoms are largely unrelated to severity of illness or ultimate disposition, though some inflammatory markers may correlate with anxiety symptoms. Over the two weeks following hospital admission, the burden of anxiety symptoms decreases significantly. However, depressive symptoms are more persistent. In addition, at two weeks following study enrollment, approximately a quarter of patients experience at least mild symptoms of acute stress disorder. These data suggest that clinicians should screen acutely ill COVID-19 patients for anxiety and depression both at initial evaluation and during follow-up and should be aware of the risk of acute stress disorder or post-traumatic stress disorder as patients recover from their acute illness.

The authors have no conflicts of interest to disclose. 

Covid-19 -Navigating the Uncharted

Mapping the Covid-19 Outbreak Globally

The psychological impact of quarantine and how to reduce it: rapid review of the evidence

The Forgotten Plague: Psychiatric Manifestations of Ebola, Zika, and Emerging Infectious Diseases

Posttraumatic stress after SARS

Psychological distress and negative appraisals in survivors of severe acute respiratory syndrome (SARS)

Addressing the COVID-19 Pandemic in Populations With Serious Mental Illness

Are we facing a crashing wave of neuropsychiatric sequelae of COVID-19? Neuropsychiatric symptoms and potential immunologic mechanisms

Psychological distress, coping behaviors, and preferences for support among New York healthcare workers during the COVID-19 pandemic

Psychological symptoms among frontline healthcare workers during COVID-19 outbreak in Wuhan. General Hospital Psychiatry

Delirium in COVID-19: A case series and exploration of potential mechanisms for central nervous system involvement

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

Neurological associations of COVID-19

Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. The Lancet Psychiatry n

Mental health status of individuals with a mooddisorder during the COVID-19 pandemic in Australia: Initial results from the COLLATE project

The mental health of frontline and non-frontline medical workers during the coronavirus disease 2019 (COVID-19) outbreak in China: a case-control study

Anxiety and depression in COVID-19 survivors: Role of inflammatory and clinical predictors

The Hospital Anxiety and Depression Scale

Training Manual and Coding Guide. Training Manual and Coding Guide Boston: Hospital Elder Life Program

MJ: Severity of Acute Stress Symptoms-Adult (National Stressful Events Survey Acute Stress Disorder Short Scale

A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation

Updating and Validating the Charlson Comorbidity Index and Score for Risk Adjustment in Hospital Discharge Abstracts Using Data From 6 Countries

Neuropsychiatric outcome in subgroups of Intensive Care Unit survivors: Implications for after-care

Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic

Chloroquine-Induced First-Episode Psychosis in a Patient Self-medicated for COVID-19

COVID-19 Psychosis: A Potential New Neuropsychiatric Condition Triggered by Novel Coronavirus Infection and the Inflammatory Response?

Epidemic psychiatry: The opportunities and challenges of COVID-19

The authors thank the primary teams involved in care of COVID-19 patients at our institution for their help in identification of potential subjects. Supported in part by the Nathaniel Wharton Fund.